Cas No.: | 1282606-48-7 |
Chemical Name: | SCD1 inhibitor-3 |
SMILES: | O=C(C1=NNC(N2C=NN(CC3=CC=C(F)C=C3)C2=O)=C1)NCC4=CC=CN=C4 |
Formula: | C19H16FN7O2 |
M.Wt: | 393.37 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1]. |
Target: | SCD1[1] |
In Vivo: | SCD1 inhibitor-3 (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %[1]. SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1]. Animal Model: Lewis rats Dosage: 5 mg/kg Administration: P.o.; 4 hours Result: Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %. Animal Model: Lewis rats Dosage: 2~10 mg/kg Administration: P.o.; 4 hours Result: A dose-responsive reduction of plasma triglycerides desaturation index. |
References: | [1]. Sun S, et al. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors. Bioorg Med Chem. 2015;23(3):455-465. |